Global Trastuzumab Market Size, Share, and Trends Analysis Report, By Type (Ogivri, Herzuma, Ontruzant, Trazimera, and Others) and By Application (Adjuvant Breast Cancer, Metastatic Breast Cancer, Metastatic Gastric Cancer, and Others), Forecast (2022-2028)

The trastuzumab market is anticipated to grow at a significant CAGR of 14.4% during the forecast period (2022-2028). Trastuzumab is a monoclonal immune response that is superior to other options for treating breast cancer. It is especially useful for bosom cancers that express the human epidermal growth factor receptor 2 (HER2) protein. It is usually used alone or in combination with other chemotherapy treatments. Trastuzumab is administered by a slow infusion just under the skin or into a vein. Disease, fever, hacking, inconvenient sleeping, cerebral ache, and rash are all common side effects of this drug, while hypersensitive reactions, cardiovascular collapse, and pulmonary illness are some of the most significant side effects. Trastuzumab use during pregnancy may be harmful to the baby. Trastuzumab acts by preventing cell duplication by inhibiting the HER2 receptor. Due to the high incidence rate and rising prevalence of bosom illness, the market is expected to grow significantly during the forecast period. These factors have prompted a slew of industry firms to try out new work methods. As a result, the present pipeline of breast cancer therapies is strong and full of potential treatments. This is expected to aid the growth of the global trastuzumab market.

The global trastuzumab market is segmented based on type and application. Based on type, the market is sub-segmented into ogivri, herzuma, ontruzant, trazimera, and others. Based on the application, the market is sub-segmented into adjuvant breast cancer, metastatic breast cancer, metastatic gastric cancer, and others. Among these applications, the adjuvant breast cancer segment is expected to propel the growth of the market due to its higher prevalence as compared to other types of applications. According to the World Health Organization (WHO), over 14.1 million new instances of cancer are diagnosed each year. Breast cancer is the second most common cancer form across the globe. Some of the most prevalent risk factors for breast cancer are genetic factors, obesity, lack of physical activity, alcohol use, advanced age, hormone replacement treatment following menopause, radiation exposure, early menstruation age, and having children at a late age.

Market Coverage

• The market number available for – 2021-2028
• Base year- 2021
• Forecast period- 2022-2028
• Segment Covered-
  • By Type
  • By Application
• Regions Covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World
• Competitive Landscape- F. Hoffmann-La Roche AG, Pfizer, Inc., Biocon Ltd., Amgen Inc., GlaxoSmithKline PLC, Novartis International AG, and Teva Pharmaceutical Industries Ltd., among others.

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How has COVID-19 impacted the market?
  • Deviation from the pre-COVID-19 forecast
  • Most affected region and segment
• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Trastuzumab Market Report by Segment

By Type

• Ogivri
• Herzuma
• Ontruzant
• Trazimera
• Others

By Application

• Adjuvant Breast Cancer
• Metastatic Breast Cancer
• Metastatic Gastric Cancer
• Others

Global Trastuzumab Market Report by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa